AstraZeneca Covid-19 Vaccine's Benefits Outweigh Risks, Says EU -- Update
16 März 2021 - 3:35PM
Dow Jones News
By Jenny Strasburg
The European Union's health authority said it is still firmly
convinced that the benefits of AstraZeneca PLC's Covid-19 vaccine
outweigh the risks, after a string of nations in the bloc
temporarily halted use of the shot over blood-clot concerns.
The European Medicines Agency so far sees no indication that the
vaccine caused a number of blood-clotting incidents reported across
Europe, Executive Director Emer Cooke said in a briefing
Tuesday.
The EU's health agency is currently reviewing those incidents to
determine whether they represent a broader risk. Ms. Cooke said the
results of the review would be presented Thursday.
She said that blood-clot incidents remain very rare, while
thousands of people continue to die from conditions related to
Covid-19.
"Trust in the safety and efficacy of the vaccines...is paramount
for us, " Ms. Cooke said. "We are worried there may be an effect on
the trust of the vaccines."
Write to Jenny Strasburg at jenny.strasburg@wsj.com
(END) Dow Jones Newswires
March 16, 2021 10:20 ET (14:20 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2024 bis Aug 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Aug 2023 bis Aug 2024
